drugset / Trial / NCT07137390
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.
Timeline
- Start
- 2025-09-03
- Primary completion
- 2026-01-22
- Completion
- 2026-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorigerlimab | Protein / enzyme biologic | — | Oral |
| Subject | Regorafenib | Small molecule | — | Oral |